Imugene HER Vaxx shows positive Overall Survival in trial
Filed with ASX · · 3 pages · English
In the deck
Story so far
Earlier from Imugene
- Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA
- Imugene Immunotherapy Combination Patent Granted in US
- Imugene Secures $5.7 million Option Underwriting Agreement
- Imugene Receives PD1-VAXX Ethics Trial Approval in USA
- Appendix 4E & Annual Report to shareholders
Later from Imugene
- Imugene First Patient Dosed in PD1-VAXX Clinical Trial
- Imugene Receives $4.82 million R&D Tax Incentive
- Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial
- Imugene completes recruitment to HER-Vaxx Phase 2 trialim
- Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene